Matt Roach
Director of Investor Relations
Replay available
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) Q1 2024 earnings conference call, held 2024-05-09. Replay captured from the company's public earnings webcast.

Director of Investor Relations
Chief Executive Officer
Chief Medical Officer
Chief Financial Officer
Analyst at Piper Sandler
Analyst at Craig Hallum
Analyst at Jefferies
Analyst at Citizens J&B
Analyst at Wells Fargo
Analyst at Capital One Securities
Thank you for standing by. My name is Cath and I will be your conference operator today. At this time, I would like to welcome everyone to the Ironwood Pharmaceuticals first quarter 2024 investor update call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, press star one again. I would now like to turn the call over to Matt Roach, Director of Industrial Relations. Please go ahead. Thank you, Cass. Good morning and thanks for joining us for our first quarter 2024 investor update. Our press release issued this morning can be found on our website. Today's call and accompanying slides include four looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties and may cause actual results to differ materially. A discussion of these statements and risk factors is available on the current Safe Harbor Statement slide, as well as under the heading Risk Factors in our annual report on Form 10-K for the year ended December 31, 2023, and in our subsequent SEC filings. All four looking statements speak as of the date of this presentation. We undertake no obligation to update such statements. Also included are non-GAAP financial measures, which should be considered only as a supplement and not a substitute for or superior to GATT measures. To the extent applicable, please refer to the tables at the end of our press release for reconciliations of these measures to the most directly comparable GATT measures. During today's call, Tom McCourt, our...